Moreover, we also found that either the CCL21 or CCR7 antibody could significantly neutralize the CCL21 effect, which provides a rationale for therapeutically targeting CCL21 as a potential novel therapeutic target for GBM. This evidence concerns the gene CCL21 and glioblastoma.